Abstract
The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.
Keywords:
clinical trials; multiantigenic; tuberculosis; vaccines.
MeSH terms
-
Antigens, Bacterial / chemistry
-
Antigens, Bacterial / genetics*
-
Antigens, Bacterial / immunology*
-
BCG Vaccine / immunology
-
Clinical Trials as Topic
-
Computational Biology / methods
-
Drug Design
-
Humans
-
Mycobacterium tuberculosis / immunology*
-
Tuberculosis / prevention & control*
-
Tuberculosis Vaccines / administration & dosage
-
Tuberculosis Vaccines / immunology*
-
Vaccines, Subunit / genetics
-
Vaccines, Subunit / immunology*
-
Vaccines, Subunit / standards
Substances
-
Antigens, Bacterial
-
BCG Vaccine
-
Tuberculosis Vaccines
-
Vaccines, Subunit